Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Accounts Payables (2019 - 2025)

Nanobiotix has reported Accounts Payables over the past 7 years, most recently at $10.6 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 50.41% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, down 50.41%, while the annual FY2025 figure was $10.6 million, 50.41% down from the prior year.
  • Accounts Payables for Q4 2025 was $10.6 million at Nanobiotix, down from $13.2 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $21.4 million in Q4 2024 and troughed at $7.4 million in Q4 2021.
  • A 5-year average of $14.1 million and a median of $11.9 million in 2025 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: skyrocketed 99.9% in 2023 and later crashed 50.41% in 2025.
  • Year by year, Accounts Payables stood at $7.4 million in 2021, then soared by 32.37% to $9.8 million in 2022, then soared by 99.9% to $19.6 million in 2023, then increased by 9.11% to $21.4 million in 2024, then crashed by 50.41% to $10.6 million in 2025.
  • Business Quant data shows Accounts Payables for NBTX at $10.6 million in Q4 2025, $13.2 million in Q2 2025, and $21.4 million in Q4 2024.